<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01345188</url>
  </required_header>
  <id_info>
    <org_study_id>IN-US-259-D032</org_study_id>
    <nct_id>NCT01345188</nct_id>
  </id_info>
  <brief_title>Ranolazine in Ischemic Cardiomyopathy</brief_title>
  <official_title>Ranolazine in Ischemic Cardiomyopathy Patients With Persistent Chest Pain or Dyspnea Despite Conventional Therapy: A Cross-Over Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Midwest Cardiovascular Research Foundation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Midwest Cardiovascular Research Foundation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with ischemic cardiomyopathy may continue to experience persistent chest pain and
      shortness of breath despite conventional medical therapy and/or revascularization. The
      purpose of this study is to determine the efficacy of taking Ranexa versus placebo in
      patients with ischemic (due to blockages) cardiomyopathy treated with optimal conventional
      medical therapy and/or percutaneous revascularization.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2011</start_date>
  <completion_date type="Actual">April 2014</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Combined endpoint of improvement in chest pain symptoms with Ranexa assessed by Standardized Angina Questionnaire or dyspnea using the Rose Dyspnea Scale (RDS)Questionnaire</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Cardiomyopathy</condition>
  <condition>Chest Pain</condition>
  <condition>Dyspnea</condition>
  <arm_group>
    <arm_group_label>Ranolazine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1000 mg Ranexa orally once daily titrated as tolerated after 1 week up to taking 1000 mg twice daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>1000 mg placebo orally once daily titrated as tolerated after 1 week up to taking 1000 mg twice daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ranexa</intervention_name>
    <description>1000 mg Ranexa orally once daily titrated as tolerated after 1 week up to taking 1000 mg twice daily.</description>
    <arm_group_label>Ranolazine</arm_group_label>
    <other_name>Ranolazine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>1000 mg placebo orally once daily titrated as tolerated after 1 week up to taking 1000 mg twice daily.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Ischemic cardiomyopathy patients on optimal medical treatment. Optimal medical
             treatment is defined as the continued symptoms of chest pain or dyspnea despite
             treatment with 2 antiischemic agents (beta blockers, CCB or nitrates). Unless
             contraindicated, all cardiomyopathy patients should be treated with a beta blocker and
             an ACEI/ARB.

          2. Anginal chest pain or dyspnea

          3. Documentation of non treatable or optimally treated coronary artery disease

          4. Ejection Fraction of less than or equal to 40%

        Exclusion Criteria:

          1. Less than 18 years of age

          2. Pregnant or breast feeding

          3. Patients with non ischemic cardiomyopathy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicolas W Shammas, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Midwest Cardiovascular Research Foundation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Midwest Cardiovascular Research Foundation</name>
      <address>
        <city>Davenport</city>
        <state>Iowa</state>
        <zip>52803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 28, 2011</study_first_submitted>
  <study_first_submitted_qc>April 28, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 29, 2011</study_first_posted>
  <last_update_submitted>September 24, 2014</last_update_submitted>
  <last_update_submitted_qc>September 24, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 25, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Midwest Cardiovascular Research Foundation</investigator_affiliation>
    <investigator_full_name>Dr. Nicolas Shammas</investigator_full_name>
    <investigator_title>Principal Investigator, MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Dyspnea</mesh_term>
    <mesh_term>Chest Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ranolazine</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>January 3, 2016</submitted>
    <returned>February 1, 2016</returned>
    <submitted>March 25, 2016</submitted>
    <returned>April 27, 2016</returned>
    <submitted>March 25, 2017</submitted>
    <returned>May 4, 2017</returned>
    <submitted>April 19, 2018</submitted>
    <returned>May 18, 2018</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

